“Technetium (99mTc) fanolesomab”的意思、由来-开放百科全书

词条

Technetium (99mTc) fanolesomab

释义

History and use
Deaths and associated recall
References
External links

{{DISPLAYTITLE:Technetium (^99mTc) fanolesomab}}{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470478210
| drug_name = Technetium (^99mTc) fanolesomab
| type = mab
| mab_type = mab
| source = o
| target = CD15
| tradename = NeutroSpec
| pregnancy_category =
| legal_status =
| routes_of_administration = Intravenous
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 225239-31-6
| ATC_prefix = none
| ATC_suffix =
| ATC_supplemental =
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| chemical_formula =
| molecular_weight =
}}

Technetium (^99mTc) fanolesomab (trade name NeutroSpec, manufactured by Palatin Technologies) is a mouse monoclonal antibody formerly used to aid in the diagnosis of appendicitis. It is labeled with a radioisotope, technetium-99m (^99mTc).

History and use

NeutroSpec was approved by the U.S. Food and Drug Administration (FDA) in June 2004 for imaging of patients with symptoms of appendicitis. It consisted of an intact murine (mouse) IgM monoclonal antibody against human CD15, labeled with technetium-99m so as to be visible on a gamma camera image. Since anti-CD15 antibodies bind selectively to white blood cells such as neutrophils, it could be used to localize the site of an infection.

Deaths and associated recall

The FDA received reports from Palatin of 2 deaths and 15 life-threatening adverse events in patients who had received NeutroSpec.

These events occurred within minutes of administration of NeutroSpec and included shortness of breath, low blood pressure, and cardiopulmonary arrest. Affected patients required resuscitation with intravenous fluids, blood pressure support, and oxygen. Most, but not all, of the patients who experienced these events had existing cardiac and/or pulmonary conditions that may have placed them at higher risk for these adverse events. A review of all post-marketing reports showed an additional 46 patients who experienced adverse events that were similar but less severe. All of the reactions occurred immediately after NeutroSpec was administered.^[1]

Marketing of the product was suspended in December 2005.

References

1. ^{{cite press release | url = http://www.fda.gov/cder/drug/advisory/technetium99.htm | title = FDA Public Health Advisory: Suspended Marketing of NeutroSpec (Technetium (99m Tc) fanolesomab) | date = December 19, 2005 | accessdate = 2007-11-27 | publisher = U.S. Food and Drug Administration}}

Walker, R, et al. Future Microbiology. 2007; 2: 527-554.
Kipper SL, et al. Journal of Nuclear Medicine. 2000; 41: 449-455.
Rypins EB, et al. Annals of Surgery. 2002; 235: 232-239.
Palestro CJ, et al. Radiology. 2002; 223: 758-764.
Love C, et al. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2006; 50: 113-120.

External links

[https://web.archive.org/web/20051029055756/http://www.micromedex.com/products/updates/drugdex_updates/de/fanolesomab.html Technetium (^99mTc) Fanolesomab] from Micromedex

5 : Monoclonal antibodies|Radiocontrast agents|Withdrawn drugs|Technetium compounds|Technetium-99m

随便看

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。